This study is looking at how a ketone supplement, called D-beta-hydroxybutryric acid and R-1,3 butanediol, affects alcohol withdrawal symptoms. Researchers want to see if this supplement helps reduce the amount of benzodiazepine medication (a type of medicine used to manage withdrawal) needed during the first four days of alcohol withdrawal treatment. You might be able to join if you are 18 to 65 years old, have moderate or severe alcohol use disorder, and are seeking treatment. The study will compare the ketone supplement to a placebo beverage (an inactive drink that looks the same). The main goal is to measure changes in benzodiazepine use after four days. The study is currently unclear about its recruitment status and plans to enroll 30 participants.

Study design

This is a 4-day randomized, double-blinded study, meaning participants are randomly assigned to either the ketone supplement or a placebo, and neither you nor the researchers will know which you are receiving. It plans to include 30 adults.

What's involved

You would take either the ketone supplement or a placebo beverage three times a day for four days, plus one dose on day five for a magnetic resonance imaging (MRI) session. You will also have an MRI session lasting 1.5 hours.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 4 days, with an additional dose on day 5 for an MRI session.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.